Brenus Pharma announces its international Scientific Committee
7.6.2023 19:00:00 EEST | Business Wire | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.
The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:
Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board
Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active member. Expertise in new drugs development.
Pr Alexander EGGERMONT MD, PhD. Pr of Oncology – Head of Clinical & Translational Immunotherapies. UMC 4, Utrecht (NL); Chief Scientific Officer. Pediatric oncology center Princessa Maxima, Utrecht. (NL)
Pr. Antoine ITALIANO MD, PhD. Pr of Oncology – Head of Early-phase trials units; Head of Precision medicine new program. Gustave Roussy, Cancer Campus Grand Paris (FR) ; Bergnonié Institute, UNICANCER Nouvelle-Aquitaine, Bordeaux. (FR)
Pr. Ignacio MELERO MD, PhD. Pr of Immunology – Head of translational immunotherapy research. CIMA 5, Navarra. (SP)
Pr Marck YARCHOAN MD. Associate Pr. of Medical Oncology at The Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins, Baltimore. (USA)
“Brenus is honored to have support & guidance of such professionals in the field. Their expertise will be instrumental in driving the first-in-human study forward and advancing the company’s mission to change a paradigm in oncology.” Benoit PINTEUR, Co-founder & CSO.
ABOUT BRENUS
Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.
For further information: www.brenus-pharma.com
____________________________
1 « Efficacy of STC-1010, a new allogeneic cancer vaccine in colorectal cancer models”
J Clin Oncol 41, 2023 (suppl 16; abstr e14661).
2 Centre de lutte contre le cancer Georges François Lecrec
3 European Society for Medical Oncology
4 University MC
5 Centro de Investigation Medical Aplicada
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005688/en/
Contact information
CONTACT BRENUS
Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Strengthens Digital Transformation and Cybersecurity Offerings with HeadMind Partners11.6.2026 16:30:00 EEST | Press release
Andersen Consulting enters into a Collaboration Agreement with HeadMind Partners, a leading European consultancy specializing in cybersecurity, digital transformation, and AI, strengthening the organization’s platform. With its unique combination of 25 years’ business experience, technology and data expertise, HeadMind Partners enables its clients, large companies from both private and public sectors, to strengthen their digital and cyber resilience, enhance their operational efficiency, and build robust and sovereign AI solutions. Headquartered in Paris and operating in France and Belgium to date, the company draws on multidisciplinary teams of 500 cybersecurity experts, 70 AI engineers and 400 digital transformation specialists to provide value-creating and seamless cybersecurity, AI and digital transformation solutions. HeadMind Partners serves a diverse and renowned client portfolio across financial services, industry, energy, luxury and the public sector. “Collaborating with Ander
Xsolla to Meet With Mobile Game Developers and Publishers at Pocket Gamer Connects Barcelona 202611.6.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced its participation in Pocket Gamer Connects (PGC) Barcelona 2026, taking place June 15-16 at the Hyatt Regency Barcelona in Barcelona, Spain. Xsolla will be on the ground for meetings with mobile game developers, publishers, and strategic partners, bringing its direct-to-consumer commerce infrastructure to one of the most deal-focused events in the European games calendar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611487209/en/ Graphic: Xsolla Now in its second year, PGC Barcelona has quickly established itself as a destination conference for mobile game businesses, drawing more than 1,000 attendees from over 47 countries and facilitating thousands of structured business meetings through its dedicated matchmaking platform. Barcelona itself has become one of Europe's most significant gaming cities, home to studios including Scopely, King, Rovio, Band
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.11.6.2026 16:00:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium on Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testingon Monday, June 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611302332/en/ Onera hPSG® – Bringing PSG Home. “We are excited to see our Onera hPSG® solution highlighted at this important meeting in three different presentations and an educational seminar. Onera hPSG® is positioned to be an integral par
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release
The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom